Clinical trials: Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT03801499
- Testing
- Lenvatinib
- Where
- China
- Sponsor
- Sun Yat-sen University
Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316)
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Biliary tract malignancies (BTC) are malignant tumors that originate from the epithelium of the bile ducts. Currently, the optimal treatment for biliary tract malignancies is radical surgical resection.
- Trial name
- ACHIEVE (NCT06607276)
- Testing
- Adebrelimab and capecitabine, capecitabine
- Where
- 4 sites in China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma, Pancreatic Neoplasms
Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure
Magnetic anastomosis has been attempted in biliary and intestinal reconstruction. Based on our initial experience, the investigators have successfully utilized magnetic anastomosis for biliojejunostomy and pancreaticojejunostomy…
- Conditions
- Cholangiocarcinoma, Pancreatic Neoplasms, Duodenal Neoplasms, Pancreatolithiasis
- Trial name
- NCT03792048
- Testing
- Magnetic Compressive Anastomosis
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pancreas Adenocarcinoma, Cholangiocarcinoma
FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1
Pancreas as well as Cholangiocarcinoma have a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease.
- Trial name
- FLUOPANC (NCT05518071)
- Testing
- CRGD-ZW800-1, Intraoperative near-infrared fluorescence imaging
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Cholangiocarcinoma, Pancreatic Cancer
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
The objective of this protocol is to establish a multicenter registry to evaluate the impact of radiofrequency ablation in the management of patients with pancreatico-biliary disorders including malignancies.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- RFA-Registry (NCT01439698)
- Testing
- Radio Frequency ablation Probe
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
ICC
Treatment of Advanced Intrahepatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.
- Trial name
- TAICC (NCT03940378)
- Testing
- Levamisole Hydrochloride, Anlotinib Hydrochloride Capsules
- Where
- China
- Volunteers
- 152 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
HER2-negative Breast Cancer, Gastric Adenocarcinoma
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Homologous Recombination Repair (HRR) gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor.
- Conditions
- HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
- Trial name
- NCT04764084
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Mixed Hepatocellular-cholangiocarcinoma
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
- Trial name
- TASK-05 (NCT07105748)
- Testing
- Camrelizumab, Rivoceranib (Apatinib), HAIC
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Colon Cancer, Gastric Cancer
A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.
- Conditions
- Colon Cancer, Gastric Cancer, Pancreas Cancer, Rectal Cancer
- Trial name
- NCT04316078
- Testing
- patient engagement platform
- Where
- Israel
- Volunteers
- 126 people
- Sponsor
- Sheba Medical Center
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocellular Carcinoma
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Selective Internal Radiotherapy is superior to Transarterial Chemoembolisation for the treatment of intrahepatic cholangiocellular carcinoma (CCC).
- Trial name
- NCT01798147
- Testing
- DEB TACE, SIRT
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Johannes Gutenberg University Mainz
Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were…
- Trial name
- NCT04413734
- Testing
- Combination therapy, Mono-chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement.
- Trial name
- NCT04353375
- Testing
- HMPL-453
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Hutchmed
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
The term of biliary tract cancer (BTC) or cholangiocarcinoma refers to all tumors that arise from the biliary tract or the biliary drainage system, including the gallbladder.
- Trial name
- NCT03937895
- Testing
- 'SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda]
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- SMT bio Co., Ltd.
Cholangiocarcinoma
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or…
- Trial name
- NCT07619937
- Testing
- HAIC Combined with Tislelizumab and Regorafenib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Bile Duct Cancer, Pancreas Cancer
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry.
Bile duct cancer and pancreatic cancer are cancers that cannot be surgically removed. As the cancer grows, it blocks the drainage of the bile ducts that carry digestive juices from the gallbladder and pancreas to the small…
- Trial name
- NCT04937322
- Testing
- Interventional Endoscopy procedures
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Methodist Health System
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Intrahepatic Cholangiocarcinoma
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment).
- Trial name
- NCT05328167
- Testing
- Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.